Cargando…
Prognostic Gene Expression Signature in Patients With Distinct Glioma Grades
BACKGROUND: Glioma is the most common type of primary brain tumor in adults. Patients with the most malignant form have an overall survival time of <16 months. Although considerable progress has been made in defining the adapted therapeutic strategies, measures to counteract tumor escape have not...
Autores principales: | Ait Ssi, Saadia, Chraa, Dounia, El Azhary, Khadija, Sahraoui, Souha, Olive, Daniel, Badou, Abdallah |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8448281/ https://www.ncbi.nlm.nih.gov/pubmed/34539626 http://dx.doi.org/10.3389/fimmu.2021.685213 |
Ejemplares similares
-
BTN3A: A Promising Immune Checkpoint for Cancer Prognosis and Treatment
por: Kone, Abdou-samad, et al.
Publicado: (2022) -
TMIGD2 as a potential therapeutic target in glioma patients
por: Boulhen, Chaimae, et al.
Publicado: (2023) -
NR2F6, a new immune checkpoint that acts as a potential biomarker of immunosuppression and contributes to poor clinical outcome in human glioma
por: Miftah, Hayat, et al.
Publicado: (2023) -
A(2A)R as a Prognostic Marker and a Potential Immunotherapy Target in Human Glioma
por: Rafii, Soumaya, et al.
Publicado: (2023) -
The immune checkpoint adenosine 2A receptor is associated with aggressive clinical outcomes and reflects an immunosuppressive tumor microenvironment in human breast cancer
por: Zohair, Basma, et al.
Publicado: (2023)